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Abstract
Background: Matrix metalloproteinases (MMPs) released by glial cells are important mediators of neuroinflammation and
neurologic damage in HIV infection. The use of antiretroviral drugs able to combat the detrimental effect of chronic
inflammation and target the exaggerated MMP activity might represent an attractive therapeutic challenge. Recent studies
suggest that CCR5 antagonist maraviroc (MVC) exerts immunomodulant and anti-inflammatory activity beyond its anti-HIV
properties. We investigated the in vitro effect of MVC on the activity of MMPs in astrocyte and microglia cultures.
Methodology/Principal Findings: Primary cultures of rat astrocytes and microglia were activated by exposure to phorbol
myristate acetate (PMA) or lypopolysaccharide (LPS) and treated in vitro with MVC. Culture supernatants were subjected to
gelatin zymography and quantitative determination of MMP-9 and MMP-2 was done by computerized scanning densitometry.
MMP-9levelswere significantlyelevatedinculture supernatantsfromboth LPS- and PMA-activatedastrocytes and microgliain
comparisonto controls. Thetreatment with MVC significantly inhibitedina dose-dependent manner the levels and expression
ofMMP-9inPMA-activatedastrocytes(p,0,05)and,toalesserextent,inPMA-activatedmicroglia.Bycontrast,levelsofMMP-2
did not significantly change, although a tendency to decrease was seenin PMA-activatedastrocytes after treatment withMVC.
The inhibition of levels and expression of MMP-9 in PMA-activated glial cells did not depend on cytotoxic effects of MVC. No
inhibition of MMP-9 and MMP-2 were found in both LPS-activated astrocytes and microglia.
Conclusions: The present in vitro study suggests that CCR5 antagonist compounds, through their ability to inhibit MMP-9
expression and levels, might have a great potential for the treatment of HIV-associated neurologic damage.
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Introduction
The widespread use of antiretroviral drugs has dramatically
modified the natural history of HIV infection, causing a significant
reduction in the HIV-associated mortality and morbidity.
However, despite complete virologic suppression under treatment,
many HIV-infected patients exhibit a persistent state of immune
activation which leads to the development of a variety of
inflammatory and metabolic pathologies (atherosclerosis, diabetes,
cancer, cirrhosis, neurocognitive disorders, metabolic abnormali-
ties) having a negative impact on the clinical progression of HIV
infection [1]. To prevent the onset of AIDS and non-AIDS related
comorbidities, it is crucial to develop strategies of intervention
capable of blocking HIV replication and down-regulating the state
of chronic inflammation.
The CCR5 antagonists are a new class of antiretroviral drugs
used for the treatment of patients infected with R5-tropic virus
[2,3]. Recent lines of evidence suggest that maraviroc (MVC), the
only CCR5 antagonist approved for clinical use, has beneficial
immunologic effects beyond its capacity to inhibit virus entry [4].
This drug might have a potential role in the downregulation of
HIV-associated chronic inflammation by blocking the recircula-
tion and trafficking of leukocytes within the inflamed tissues.
Leukocyte trafficking and local inflammation plays a prominent
role in the physiopathology of HIV infection of the central nervous
system (CNS) [5]. Indeed, the development of HIV-associated
neurological disorders is associated with increased migration of
leukocytes into the CNS, which can disrupt the blood-brain
barrier (BBB) and propagate neuroinflammation. These patho-
logic processes result in BBB permeability, glial activation, and
neuronal compromise, all of which contribute to CNS damage [6].
The entry of leukocytes into the CNS is dependent in several
factors including the expression of matrix metalloproteinases
(MMP) [7].
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degrade extracellular matrix and basement membrane compounds
(collagens, gelatin, laminin, fibronectin) [8]. They share common
structural domains, but differ with respect to their cellular sources,
inducibility and efficiency of substrate utilization. The expression
and the activity of MMPs are tightly regulated. Most of the
regulatory mechanisms mediated by soluble factors occur
primarily at the transcriptional level and involve phosphorilaton
of serine-threonine kinases related to the mitogen-activated
proteine kinase (MAPK) superfamily [9]. Posttranscriptional
regulation of MMPs includes their secretion as latent enzymes
and proenzyme activation in the extracellular milieu by different
proteinases. Inhibition of MMP activation and proteolytic activity
in the extracellular milieu is controlled by a unique family of
natural tissue inhibitors (TIMPs) which form with active MMPs
stable, non-covalent enzyme-inhibitor complexes [10].
There is evidence that an altered production and secretion of
MMPs and TIMPs might be involved in the development of HIV-
associated brain injury, contributing to breakdown of the BBB,
spreading of HIV into CNS, degradation of myelin and induction
of neuronal death [11,12]. Brain macrophages, microglia and
astrocytes represent the candidate cells for the production of MMP
within the CNS.
In previous studies, we demonstrated that antiretroviral drugs
inhibit MMP-2 and MMP-9 secretion and expression in LPS-
stimulated astrocytes and microglia [13]. More recent data shows
that antiretroviral compounds can also significantly downregulate
the expression of MMP-9 in HIV-naturally infected mononuclear
cells [14], indicating that antiretroviral drugs may mitigate MMP-
mediated damage by mechanisms that are independent from their
ability to block HIV replication. These findings may have great
therapeutic implications, suggesting that MMPs may represent a
potential target for the development of adjunctive strategies for the
management of HIV infection, especially within CNS [12].
On the basis of these observations, since the release of MMPs
from glial cells may represent a key event in the pathogenesis of
HIV-associated demyelination, we investigated whether CCR5
antagonist MVC was able to modulate the activity and/or the
expression of gelatinases A (MMP-2) and B (MMP-9) released
from glial cells. Our results indicated that MVC is able to dose-
dependently inhibit the release and the expression of MMP-9 from
PMA-activated astrocyte cell cultures.
Materials and Methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine
serum (FBS), penicillin and streptomycin were obtained from
GIBCO (Paisley, Scotland). Gelatin, DNase 1, poly-L-lysine (PLL),
trypsin, lipopolysaccharide (LPS), 1,10 phenanthroline (PA),
Trypan Blue, Thiazolyl Blue Tetrazolium Bromide (MTT) were
provided by Sigma (St. Louis, MO, USA.). Maraviroc (MVC)
(Celsentri) was from Pfizer, Inc. (New York, NY, USA). Standard
proteins and R-250 Coomassie Brilliant Blue were purchased from
Bio-Rad (Hercules, CA, USA).
Anti glial fibrillary acidic protein (GFAP) antibodies were
purchased from Serotec (Oxford, UK). Purified MMP-2 and
MMP-9 were purchased from Alexis Biochemicals (San Diego,
CA, USA). The MMP-9 was derived from human neutrophil
granulocytes and thus also contained covalent MMP-9-NGAL
complex. Primer pairs specific for MMP-2, MMP-9 and GAPDH
were from Sigma Genosys (Cambridge, UK). RNeasy mini kit and
QuantiTect Reverse Transcription was from Qiagen (Valencia,
CA, USA).
Cell cultures
Ethics Statement. All experimental procedures involving
animals were carried out in accordance with the NIH Guide for
the Care and Use of Laboratory Animals and approved by the
Institutional Animal Care and Use Committee of University of
Bari, Italy. All efforts were made to minimize the number of
animals used and to ameliorate their suffering.
Preparation of microglial and astrocyte cultures. Microglial
cells were prepared from primary cell cultures of neocortical tissues
from 1-day-old rats as described by Nakajima et al. [15]. Briefly,
brains were cleaned of meninges and blood vessels, and the dissected
neocortical tissues were minced by passage through a stainless steel
mesh (40 mesh) and incubated with 0.25% trypsin and 0.01% DNase
in DMEM for 10 min at 37uC. After addition of FBS, the dissociated
cells were passed through a 100 mesh and viability of cells was assessed
by Trypan Blue dye exclusion. Cells were plated in PLL-coated flasks
(75 cm
2)a tad e n s i t yo f1 . 5 610
7 viable cells/flask in DMEM, 100 U/
ml penicillin, 100 mg/ml streptomycin, 10% FBS and maintained at
37uC in a 5% carbon dioxide incubator with a renewal of medium
twice a week. After 7–10 days in culture, the flasks were shaken for
10 min at 100 r.p.m. on a rotary shaker and the cells floating into the
medium were transferred to plastic dishes and allowed to adhere at
37uC. Unattached cells were removed after 1 h by washing with
DMEM. The strongly adhering cells showed a homogeneous
morphology characteristic of microglia as reported by several
authors [16,17]. By immunocytochemical analysis, .98% of the
cells stained positively with anti-mouse monocyte/macrophage
antibody and were negative with anti-GFAP antibodies.
For the preparation of astrocyte cultures, oligodendrocytes were
separated from the astrocytes by mechanical dislodging and then
the astrocytes were obtained by trypsinization (0.25% trypsin/
0.02% EDTA) [17]. Astrocytes were purified by three repetitions
of replating and trypsinization to deplete cultures of microglia and
oligodendrocytes. The purity of the final cell culture was assessed
by immuno-staining for GFAP. More than 98% of the cells were
GFAP-positive in all the preparations.
In vitro MVC treatment of microglia and astrocytes
activated with LPS or PMA. One day after seeding at a
density of 1610
5 cells/ml in 96 well-plates, the microglial cells and
astrocytes were washed once serum-free DMEM, activated with
LPS at the final concentrations of 10 mg/ml or with PMA 100 nM
and simultaneously treated with MVC at the final concentrations
of 0.2 nM, 2 nM, 20 nM and 200 nM. Negative and positive
control supernatants were obtained from unstimulated and
untreated microglial cells and astrocytes in serum-free DMEM
(negative control), cells stimulated with LPS or PMA (positive
control). The incubations were performed in a final volume of
100 ml of serum-free DMEM for 24 h at 37uC, 5% carbon dioxide
(CO2). At the end of the incubation period, the medium was
collected, centrifuged at 2100 rpm and cell culture supernatants
stored at 220uC until use. The cells were subjected to the test of
cell viability by MTT or lysed for RNA isolation.
MTT cell viability assay
Cytotoxicity of astrocyte and microglial cells after LPS or PMA-
activation and treatment with MVC was detected using MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay
[18]. This assay is based on the reduction of MTT by the
mitochondrial succinate dehydrogenase in viable cells, to a blue
formazan product which can be measured spectrophotometrically
using a microplate reader.
Briefly, after treatment for 24 h with MVC the culture medium
was removed and cells were rinsed in PBS and incubated at 37uC,
5% CO2 for 2 h with 0.5 mg/mL MTT. Reaction was stopped by
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solubilized with absolute ethanol. The absorbances at 560 and
690 nm were determinated by a VersaMax Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA). The difference
between the absorbance of each sample at 560 and 690 nm was
measured. The value of the untreated sample (control) was set at
100% and the cell viability was expressed as percentage of control.
Detection of gelatinases
Gelatinases in cell culture supernatants were determined by
sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) zymography according to a modification of the method of
[19] as described by [13]. Briefly, 50 ml of culture supernatant was
supplemented with 30 ml of electrophoresis- loading buffer
containing SDS. The samples were then separated in a 7.5%
polyacrylamide gel which had been copolymerized with 0.1% (w/
v) gelatin. Stacking gels contained 5.4% polyacrylamide. The
electrophoresis was performed at 4uC for ,18 h at 80 V. After
electrophoresis, the gels were washed for 2620 min in 2.5% (w/v)
Triton X-100/10 mM CaCl2 in 50 mM Tris-HCl, pH 7.4
(washing buffer) in order to remove SDS, and then incubated
for 24 h at 37uC in 1% (w/v) Triton X-100/50 mM Tris-HCl/
10 mM CaCl2, pH 7.4 (developing buffer). For the development
of the enzyme activity, the gels were stained with Coomassie
Brilliant Blue R-250 and destained in methanol/acetic acid/water.
Gelatinase activity was detected as a white band on a blue
background and was quantified by computerized image analysis
through two-dimensional scanning densitometry using the Image
Master 1D program (Pharmacia Biotech, Uppsala, Sweden).
Gelatinase activity was expressed as optical density (OD)6mm
2,
representing the scanning area under the curves which takes into
account both brightness and width of the substrate lysis zone.
Reverse Transcription-polymerase chain reaction
(RT-PCR)
Total cellular RNA was extracted from astrocyte cells using the
Qiagen RNeasy mini kit according to the manufacturer’s
instructions. The concentration and purity of the isolated RNA
were determined by using the NanoDrop 1000 spectrophotometer
(Thermo scientific).
Complementary DNA (cDNA) was synthesized from 500 ng
RNA by using the QuantiTect Reverse Transcription kit
according to manifacturer’s instructions. A total of 1 ml of reverse
transcription products was used to amplify a 591 bp fragment
using specific primers (sense 59-GTC ACT CCG CTG CGC TTT
TCT CG-39; antisense 59-GAC ACA TGG GGC ACC TTC
TGA-39) for the rat MMP-2 sequence and a 541 bp fragment
using specific primers (sense 59-CGG AGC ACG GGG ACG
GGT ATC 39; antisense 59-AAG ACG AAG GGG AAG ACG
CAC ATC 39) for the rat MMP-9 sequence. Amplification of a
308 bp fragment of rat GAPDH (sense 59-TCC CTC AAG ATT
GTC AGC AA-39; antisense 59-AGA TCC ACA ACG GAT
ACA TT-39), a relatively invariant internal reference RNA, was
performed in parallel. Twenty-five cycles of PCR were carried out,
Figure 1. Effect of MVC treatment on MMP-2 and MMP-9 levels in astrocyte culture supernatants. Primary astrocytes (1610
5 cells/ml),
incubated in serum-free DMEM, were treated with MVC at the indicated concentrations in the presence of PMA (100 nM) (A) or LPS (10 mg/ml) (B).
Negative and positive control supernatants were obtained from unstimulated and untreated astrocytes in serum-free DMEM (control) and cells
stimulated with LPS or PMA, respectively. After 24 h of incubation equal amounts of cell culture supernatants were subjected to gelatine zymography
as described in the Methods section. Representative gels are reported in (A) and (B). MMP-2 and MMP-9 were identified by their apparent molecular
mass of 67 and 92 kDa, respectively, using pre-stained molecular weight markers (Bio-Rad). Histograms represent results, expressed as mean6SD,
after scanning densitometry and computerized analysis of gels, from at least three independent experiments with different cell populations. Asterisk
represents values statistically different from positive control (PMA-treated astrocytes) (One-way Anova followed by Student-Newman-Keuls post hoc
test; *=p,0.05).
doi:10.1371/journal.pone.0028499.g001
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and extension at 72uC in a thermal cycler (PTC- 100
Programmable Thermac Controller, MJ Research, Inc., Walthan,
MA, USA). PCR products were visualized by ethidium bromide
staining in 1.5% agarose gels. Gels were then processed for
densitometric analysis as described for protein gels. Amplification
of the target cDNAs were normalized to GAPDH expression.
Statistical analysis
Data from at least three different experiments were used for
statistical analysis. Original data were converted into %-values of
positive control and mean6 SD was calculated. Values were
compared using one-way analysis of variance (ANOVA) followed
by the post-hoc Student Newman-Keuls test (multiple compari-
son).
Results
Maraviroc reduces MMP-9 levels in PMA-stimulated
astrocytes but not in LPS-stimulated astrocytes
Primary astrocytes were stimulated with PMA or with LPS and
simultaneously treated with different concentrations of MVC in
serum-free DMEM. Cell supernatants collected after 24 h incuba-
tion were subjected to gelatin zymography for the assessment of
MMP-2 and MMP-9 levels. As shown in the representative gels in
Fig. 1, cell culture supernatants from untreated and unstimulated
astrocytes (control) secreted only the 67 kDa MMP-2 and traces of
the 92 kDa MMP-9. LPS or PMA-activation of astrocytes
significantly induced MMP-9 as well as MMP-2 levels when
compared with those detected in negative controls. The in vitro
treatment with MVC dose-dependently inhibited levels of MMP-2
and MMP-9 in PMA-activated astrocytes (Fig. 1A), whereas it has
no effect on both MMP-9 and MMP-2 levels in LPS-activated
astrocytes (Fig. 1B). The quantitation of the data from at least three
experiments with different cell populations indicated that the
treatment with MVC at the highest concentration of 200 nM
induced in PMA-activated astrocytes a statistically significant
inhibition of MMP-9 (Fig. 1A). Concerning MMP-2, although the
treatment of PMA-activated astrocytes with MVC reduced MMP-2
to levels found in control conditions, the statistical analysis of data
indicated that this inhibition is not significant.
The analysis of the effect of MVC on microglial cells showed no
inhibition of MMP-2 in both PMA- and LPS-activated cells. With
regard to MMP-9, a 25% decrease of MMP-9 levels was observed
in PMA-activated microglia (Fig. 2), although this inhibition was
not statistically significant.
Cytotoxicity of astrocytes after treatment with maraviroc
As shown in Fig. 3A in the absence of stimulation cultured rat
astrocytes exhibited a flattened, polygonal morphology, typical of
Figure 2. Effect of MVC treatment on MMP-2 and MMP-9 levels in microglial culture supernatants. Primary microglial cells (1610
5 cells/
ml), incubated in serum-free DMEM, were treated with MVC at the indicated concentrations in the presence of PMA (100 nM) or LPS (10 mg/ml).
Negative and positive control supernatants were obtained from unstimulated and untreated microglia in serum-free DMEM (control) and cells
stimulated with LPS or PMA, respectively. After 24 h of incubation equal amounts of cell culture supernatants were subjected to gelatine zymography
as described in the Methods section. Representative gels in A and B show MMP-2 and MMP-9, as identified by their apparent molecular mass of 67
and 92 kDa, respectively, using pre-stained molecular weight markers (Bio Rad). Histograms represent results, expressed as mean6SD, after scanning
densitometry and computerized analysis of gels, from at least three independent experiments with different cell populations. No statistically
significant inhibition of MMP-2 and MMP-9 in both PMA- and LPS-activated cells was observed. (One-way Anova followed by Student-Newman-Keuls
post hoc test).
doi:10.1371/journal.pone.0028499.g002
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induced a change in a process-bearing stellate morphology,
characteristic of reactive astrocytes. This latter morphology was
displayed also by PMA-activated astrocytes treated with the lowest
concentration of MVC. By contrast, when PMA-activated astro-
cytes were treated with 200 nM MVC, cell morphology did not
change compared to that of control cells.
As assessed by the microscopical observation (Fig. 3A) and the MTT
assay (Fig. 3B) we did not observe any significant variation in the
number of astrocytes between PMA-stimulated and MVC treated cells,
indicating that at all concentrations used in this study, MVC alone or
together with PMA did not show cytotoxicity to astrocyte cells.
Maraviroc does not directly inhibit the activity of purified
MMP-2 and MMP-9
In an in vitro assay, we also tested the ability of MVC to inhibit
MMP-2 and MMP-9. To do this, 0.88 ng of purified MMP-9 and
0.35 ng of purified MMP-2 were separated by gelatin zymography
and the zymogram was incubated in developing buffer containing
MVC at the final concentrations of 2 nM, 20 nM and 200 nM. As
a control, MMP-2 and MMP-9 were incubated in the presence of
4 mM 1,10 phenantrolin (PA), an inhibitor of MMPs. As showed
in Fig. 4, PA treatment completely blocked the activity of both
MMP-2 and MMP-9, whereas MVC did not exert any direct
inhibition on the enzymatic activity of MMP-2 and MMP-9.
Figure 3. Effect of MVC on astrocyte morphological changes and cell viability. Primary astrocytes (3610
4), were activated with PMA
100 nM and simultaneously treated with different concentrations of MVC for 24 h at 37uC, 5%CO2 in serum-free DMEM (Control). (A)
Photomicrographs show representative results of three independent experiments. Cell morphology was observed under phase-contrast microscope
(Magnification 506). (B) Cell viability was examined by MTT assay. The results are expressed as percentage of surviving cells over control cells. Data
are presented as mean 6 SD for three separate experiments with independent cell populations.
doi:10.1371/journal.pone.0028499.g003
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maraviroc
To determine whether the inhibition of MMP-9 levels by MVC
in PMA-stimulated astrocytes results from the inhibition of mRNA,
RT-PCR was performed. As shown in Fig. 5A, MVC dose-
dependently inhibited the PMA-induced expression of MMP-9
mRNA, whereas the expression of MMP-2 and GAPDH mRNA, a
housekeeping gene product used as an internal control, was
unchanged. Quantitation of results from independent experiments
with different cell populations, after normalization with GAPDH,
showed a statistical significant inhibition of MMP-9 expression in
cells treated with the highest concentration of MVC (Fig. 5B). The
RT-PCR of microglial cells gave results which were consistent with
the data observed by zymography (data not shown).
Discussion
Despite the success of antiretroviral therapy (ART) in
controlling HIV replication and disease progression, HIV-
associated neurological disorders remain an important clinical
challenge that still affect nearly 50% of HIV-infected individuals
[20,21]. In particular, several data suggest that HIV may continue
to affect the brain even in the presence of effective ART [22,23].
The large majority of brain-derived HIV strains use mainly CCR5
coreceptor for gaining access into the CNS. It is known that CCR5
has been involved in lymphocyte and mononuclear phagocyte
recruitment in the CNS of various neuroinflammatory diseases,
including HIV infection [24,25]. Therefore, particular attention
has been dedicated to drugs able to target selectively the CCR5
coreceptor, such as CCR5 antagonists.
Figure 4. Zymographic analysis of MMP-2 and MMP-9 activity after in vitro incubation with MVC. Purified standard MMP-2 (0.35 ng) and
MMP-9 (0.88 ng) were subjected to gelatin zymography as described in the text. After the electrophoresis, the gel was cut into lanes and each lane
was incubated in the absence (control) or in the presence with MVC at the reported concentrations during the development of the zymograms. 1,10
phenantroline (4 mM) (PA) was used as a positive control. A: Staining and destaining of the gels revealed that inhibition of both MMP-2 and MMP-9
activity was observed only in the lane incubated in the presence of PA, but not in the lanes developed in the presence of MVC. B: Percentage of MMP-
9 and MMP-2 inhibition of repeated analyses calculated in comparison to control.
doi:10.1371/journal.pone.0028499.g004
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for the management of HIV infection. Since this drug has been
recently introduced into clinical practice, most of its extravirolo-
gical effects on other factors which are possible causes of
development of neurological syndromes remain to be clarified.
In this paper, we studied the effects induced by MVC on the
synthesis and the release of MMPs by glial cells and we showed
evidence of the ability of this drug to inhibit the release and the
expression of MMP-9 and, to a lesser extent of MMP-2, in PMA-
activated astrocytes. A slight but not significant inhibition of
MMP-9 was also seen in PMA-activated microglial cells after in
vitro MVC treatment.
HIV infection of host cells has been shown to trigger the
expression of MMPs, in particular MMP-9 [26,27]. The increased
levels of MMP-9 by leukocytes facilitate their entry into CNS. This
process disrupts the basement membrane that surrounds the
vasculature, resulting in blood–brain barrier (BBB) impairment.
Within the CNS parenchyma, brain macrophages, microglia and
astrocytes not only replicate the virus actively but also play an
important role in HIV-associated neural injury through the
production of inflammatory mediators and various neurotoxins,
including MMPs [28]. In the CNS, high MMP content and its
indiscriminate localization results in perpetuation of an inflamma-
tory response, which contributes to demyelination and neuronal or
oligodendrocyte death. In the light of these considerations, MMPs
can be considered as an important target for an innovative
therapeutic approach in alternative or in addition to the
pharmacological therapy, especially for HIV-associated neurologic
disorders for which we have no specific therapies so far. In previous
studies, we showed that antiretroviral drugs, particularly HIV
protease inhibitors, are capable of inhibiting MMP-2 and MMP-9
secretion and expression in LPS-stimulated astrocytes and microglia
[13]. More recent data indicate that antiretroviral compounds can
also significantly downregulate the expression of MMP-9 in
mononuclear cells naturally infected with HIV [14]. These findings
could have great therapeutic implications, suggesting that antiret-
roviral drugs might counteract MMP-mediated damage inthebrain
by mechanisms that areindependent from their capacity to suppress
HIV replication. On the other hand, the ability of antiretroviral
drugs, especially protease inhibitors, to exert extravirologic effects at
various cellular patways has been previously demonstrated [29,30].
MVC through the ability of downregulate MMP expression in
rat astrocytes might contribute to counteract the chronic activation
of glial cells into the CNS, thus limiting the progression of
demyelination and neurodegeneration associated with HIV
infection. In this respect, the morphological changes observed in
MVC-treated astrocytes compared with those activated with
PMA, may suggest that at the cellular level MVC may act by
counteracting the activation of astrocytes.
To explain the reduced effect of MVC on MMP-9 levels in
microglial cells, we detected the expression levels of CCR5 in
astrocytes and microglia by using real-time PCR. As a result, we
found similar levels of CCR5 on both cell populations in basal
conditions as well as in PMA-activated cells, suggesting that that
the different effect of MVC on the two cell populations do no
depend from levels of CCR5 (data not shown). A possible
explanation for the reduced inhibitory effect of MVC on MMP-9
in microglial cells may arise from the observation that microglia
are the most reactive cell population of brain parenchyma.
Microglia rapidly transform from a resting to an activated
morphology in response to different inducers such as LPS, PMA,
cytokines and chemokines. The products of activated microglia are
pro-inflammatory cytokines, chemokines, nitric oxide, superoxide
radicals which, in turn, may induce the production of MMP-9.
Therefore, the induction of MMP-9 in activated microglial cells
may be due to the cooperative interaction of multiple signaling
pathways suggesting that the functional interplay of these
pathways may in part counteracts the inhibitory effect of MVC.
Recent findings suggest that CCR5 antagonists could have
immunomodulant properties beyond the pure anti-HIV inhibitory
activity [31,32]. By preventing signalling through the CCR5
receptor, CCR5 antagonists may downregulate immune activa-
tion, T-cell apoptosis and cytokine expression. In a recent study,
we provided evidence that that PBMCs from HIV-infected
patients exhibited diminished chemotactic migration following in
vitro and ex vivo treatment with CCR5 antagonist MVC [33].
Moreover, in a set of in vitro experiments, we demonstrated that
MVC was able to downregulate the migration of innate immune
cells, such as monocyte/macrophages and dendritic cells [34].
These data findings suggest that CCR5 antagonists might have a
potential role in reducing the severity of neuroinflammation by
targeting the CCR5-leukocyte recruitment pathway to the CNS.
On the other hand, experimental data in a murine model of
demyelination showed that an anti-CCL5 monoclonal antibody
Figure 5. Inhibition of MMP-9 mRNA expression in PMA-
activated astrocytes by MVC. Primary astrocytes (1610
5 cells/ml),
incubated in serum-free DMEM (Control), were activated with 100 nM
PMA (positive control) and simoultaneusly treated with MVC at the
indicated concentrations. The isolated RNA samples were analyzed by
RT-PCR, using the primer pairs specific for MMP-2, MMP-9 and GAPDH.
The products were run on a 1,5% agarose gel containing ethidium
bromide. The bands were visualized under UV. Representative results
are shown in A. Quantitation of the above experiment and two others
after scanning densitometry are shown in B. Positive control MMP-2 and
MMP-9 mRNA were set at 100%, and the treatments with MVC
represented as percent of positive control (mean6 SD). Asterisk
indicates statistically significant decrease in comparison to positive
control. (One-way Anova followed by Student-Newman-Keuls post hoc
test; *=p,0,05).
doi:10.1371/journal.pone.0028499.g005
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improves neurological function [35]. On the basis of these
considerations, the use of CCR5 antagonists for the management
of HIV brain infection could have a double therapeutic effect:
blocking viral entry and counteracting leukocyte recruitment and
neuroinflammation.
To study the effect of MVC we activated glial cells with two
different immunogens that can stimulate the release of MMP-9
with different mechanisms of action. In particular, LPS interacts
with CD14 and, by triggering the cascade of the mitogen-activated
protein kinase (MAPK) downstream of Toll-like Receptor-4 (TLR-
4), induces the expression of MMP-9 [36–38]. The PMA,
however, crosses the plasma membrane and induces the
expression of MMP-9 through activation of MAPK mediated by
protein kinase C (PKC) [39].
In our experiments, we demonstrated the ability of MVC to
inhibit the expression of MMP-9 in PMA- but not LPS-activated
astrocytes. This result could be explained by considering the
mechanism of action of MVC at the cellular level.
MVC is a CCR5 antagonist that, by binding to the chemokine
receptor, prevents the conformational change of the gp120 viral
protein, which is necessary for viral entry into cells, and inhibits
the cascade downstream of the receptor for chemokines, by
inactivating PKC. Therefore, MVC may act by inhibiting in part
the activation of PKC by PMA, thus downregulating the
expression of MMP-9. By contrast, the lack of inhibition of
MMP-9 by MVC in LPS-activated, could be explained consider-
ing that the signal transduction pathway activated by LPS could
occur with a PKC-independent mechanism.
This hypothesis that MVC interferes with the activation of
MMP-9 at level of gene transcription is also confirmed from the
experimental observation that this drug inhibits the expression but
not the activity of MMP-9, as demonstrated in our experiments
with RT-PCR and in vitro zymography. On the other hand, we
can exclude that the reduction of MMP-9 levels and expression,
observed in PMA-activated astrocytes by MVC, may be due to
cytotoxic effects of this drug. In fact, both the microscopic
observation and the cytotoxicity test demonstrate that there are no
variations in the number of cells. The present in vitro study
suggests that CCR5 antagonist compounds might have a great
potential for the treatment of HIV-associated neurological
damage. In particular the beneficial effect of MVC could be
ascribed to three mechanisms of action: i) inhibition of HIV entry
by blocking the interaction between HIV and the chemokine
receptor CCR5, that is necessary for the virus to enter host cells.;
ii) downregulation of migration of HIV-producing cells across BBB
as consequence of CCR5 inhibition; iii) direct inhibition of MMP
levels in astrocytes with a mechanism that is independent from its
antiviral activity. These findings might have clinical implications
on the impact of CCR5 antagonists in neurological diseases
associated with MMPs involvement.
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